There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Theseus Pharmaceuticals Inc (THRX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.30%, to $3.29. The Theseus Pharmaceuticals Inc has recorded 33,923 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $3.30 and fluctuated between $3.5000 as its day high and $3.1900 as its day low. The current market capitalization of Theseus Pharmaceuticals Inc is $143.88M. A total of 2.12 million shares were traded on the day, compared to an average of 481.87K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, THRX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 11 BUYs and 0 SELLs from insiders. Insiders purchased 2,171,366 shares during that period but sold 0.
In the most recent transaction, Foresite Capital Management V, bought 700,000 shares of THRX for 2.97 per share on Jul 17. After the transaction, the 10% Owner now owns 4,108,796 company shares. In a previous transaction on Jul 17, GORDON CARL L bought 479,932 shares at 3.05 per share. THRX shares that Director owns now total 17,063,000.
Among the insiders who bought shares, ORBIMED ADVISORS LLC acquired of 479,932 shares on Jul 17 at a per-share price of $3.05. This resulted in the Director holding 17,063,000 shares of THRX after the transaction. In another insider transaction, HAYDEN DONALD J JR bought 9,900 shares at $5.00 per share on Dec 30. Company shares held by the Director now total 10,000.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for THRX in the last 3 months, the mean price target is $6.70 with high estimates of $10.00 and low estimates of $3.50. In terms of 52-week highs and lows, THRX has a high of $14.77 and a low of $2.05.
As of this writing, THRX has an earnings estimate of -$0.36 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.32 per share and a lower estimate of -$0.39. The company reported an EPS of -$0.34 in the last quarter, which was 19.00% higher than expectations of -$0.42.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. THRX’s latest balance sheet shows that the firm has $244.66M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was $5.37, while its Total Shareholder’s Equity was $246.43M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for THRX is Buy with a score of 4.33.